Sanofi’s $1.7 billion rare disease bet from last year has delivered a phase 2 win. | Sanofi’s $1.7 billion rare disease bet ...

Ipsen is acquiring next-gen immuno-oncology biotech ImCheck Therapeutics for its investigational cancer combination therapy ...

Takeda is paying Innovent Biologics $1.2 billion upfront for rights to two cancer candidates. The deal, which includes (PDF) ...

Boston Scientific’s third-quarter revenue topped $5 billion, up 20.3% year over year. Growth eased slightly from the second ...

Thermo Fisher Scientific’s plan for growth is paying off as the biopharma service provider and supplier posted a sales bump ...

In one of the biggest healthcare acquisitions of its kind this year, medtech diagnostics specialist Hologic will go private ...

Electra Therapeutics is incandescent, glowing on the heels of a $183 million series C financing intended to fuel the ...

Following three years of internal development, Expedition Medicines is taking flight. The company is supported by a $50 ...

Terns Pharmaceuticals has shelved its oral GLP-1 obesity candidate after a phase 2 trial delivered a mix of weight loss and ...

Moderna’s oncology pipeline also includes a Merck-partnered personalized cancer vaccine called intismeran autogene or ...

With $70 million and a phase 2 ready asset in hand, British biotech Elevara Medicines has emerged to try to revolutionize the ...

While most of what the FDA laid out in a recent draft guidance on the assessment of overall survival in oncology clinical ...